CD8A and acute lymphoblastic leukemia: One recent clinical trial at Fred Hutchinson used this selective approach by infusing a 1:1 ratio of CD4+ and CD8+ cells with a central memory (CM) signature to treat patients with B-ALL; however, only 16 of the 30 patients had enough CD8+ TCM cells in the peripheral blood to meet their minimum criteria to enrich this population (105).